Wang Li-Li, Liu Wen-Jia, Liu Hai-Yun, Xu Xun
Department of Ophthalmology, Shanghai First People's Hospital, Shanghai 200080, China.
Chin Med J (Engl). 2015 May 5;128(9):1154-9. doi: 10.4103/0366-6999.156083.
Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss among the older population. In China, treatment of age-related ocular diseases is becoming a priority in eye care services. This study was to investigate the clinical characteristics and quality of life of Chinese patients with wet AMD and current treatment types, to evaluate short-term gains in different treatments, and to investigate associations between visual function and vision-related quality of life (VRQoL).
A prospective, observational, noninterventional study was conducted. Basic data were collected from patients with clinical diagnoses of wet AMD before clinical assessments at baseline. VRQoL was measured with the Chinese version of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25). Correlations of the NEI VFQ-25 subscale scores with best-corrected visual acuity (BCVA) and between-group differences were analyzed.
A total of 80 wet AMD patients were enrolled, with the mean age of 68.40 years. About one-quarter of wet AMD patients received intravitreal (IVT) ranibizumab treatment, and 67% of them were treated on a pro re nata basis. The visual acuity of patients treated with IVT ranibizumab at month 3 after treatment was significantly increased, whereas patients treated with traditional Chinese medicine achieved no significant improvement. Cronbach's α for the NEI VFQ-25 subscales ranged from 0.697 to 0.843. Eight subscale and overall composite scores were moderately correlated with the BCVA of the better-seeing eye. Significant differences in the overall NEI VFQ-25 scores and other subscales were observed between patients with BCVA in the better-seeing eye of less than 50 letters and the others.
Patients treated with IVT ranibizumab experienced better vision improvement at short-term follow-up. The Chinese version of the NEI VFQ-25 is a valid and reliable tool for assessing the VRQoL of Chinese wet AMD patients.
年龄相关性黄斑变性（AMD）是老年人群不可逆视力丧失的主要原因。在中国，年龄相关性眼病的治疗正成为眼保健服务的重点。本研究旨在调查中国湿性AMD患者的临床特征、生活质量及当前治疗类型，评估不同治疗的短期疗效，并探讨视觉功能与视力相关生活质量（VRQoL）之间的关联。
进行一项前瞻性、观察性、非干预性研究。在基线临床评估前，收集临床诊断为湿性AMD患者的基础数据。采用中文版的美国国立眼科研究所视觉功能问卷25项（NEI VFQ-25）测量VRQoL。分析NEI VFQ-25各分量表得分与最佳矫正视力（BCVA）的相关性以及组间差异。
共纳入80例湿性AMD患者，平均年龄68.40岁。约四分之一的湿性AMD患者接受玻璃体内（IVT）注射雷珠单抗治疗，其中67%按需治疗。IVT注射雷珠单抗治疗3个月后的患者视力显著提高，而接受中药治疗的患者无显著改善。NEI VFQ-25各分量表的Cronbach's α系数在0.697至0.843之间。8个分量表及总体综合得分与较好眼的BCVA中度相关。较好眼BCVA低于50个字母的患者与其他患者之间，NEI VFQ-25总体得分及其他分量表存在显著差异。
IVT注射雷珠单抗治疗的患者在短期随访中视力改善更好。中文版NEI VFQ-25是评估中国湿性AMD患者VRQoL的有效且可靠工具。
